Chinese Journal of Integrative Medicine最新文献

{"title":"Hyperoside Exerts Therapeutic Effects on Parkinson's Disease by Mitigating Oxidative Stress through Activation of Nrf2/HO-1 Pathway.","authors":"Si-Xiang Niu, Li-Shan Fan, Jing-Yi Cheng, Lei Xu, Li-Xia Yang, Sheng-Nan Xiao, Rui-Rui Sun, Shao-Chen Qin, Bao-Guo Xiao, Hui-Jie Fan, Zhi Chai","doi":"10.1007/s11655-026-4160-6","DOIUrl":"https://doi.org/10.1007/s11655-026-4160-6","url":null,"abstract":"<p><strong>Objective: </strong>To investigate whether hyperoside (HYP), the main active ingredients of Wuzi Yanzong Pill, can reduce oxidative stress (OS) damage and treat Parkinson's disease (PD) by activating the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway.</p><p><strong>Methods: </strong>MPTP-induced PD mouse model was established and animals were divided into 5 groups by random number table method: control group, MPTP group (15, 20, and 30 mg/kg on days 1, 2 and 3-7, respectively), and MPTP+HYP low-, medium-, and high-dose groups (25, 50, and 100 mg·kg^-1·d^-1, respectively). Behavioral tests were conducted and protein expression levels of tyrosine hydroxylase (TH), Nrf2, HO-1, B-cell lymphoma 2 (Bcl-2), and Bcl-2-associated X protein (Bax) were analyzed using Western blot. Glutathione (GSH), glutathione peroxidase (GSH-Px), malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT) levels were measured by ELISA. Molecular docking and dynamics simulations were performed on HYP and Nrf2, and neuronal apoptosis was detected by TUNEL assay. Multivariate statistical analysis was used to investigate the correlation between HYP's therapeutic effect on PD and OS via the Nrf2/HO-1 pathway. In the SH-SY5Y cell model (MPP⁺ and ML385), cell viability and toxicity were assessed with cell counting kit-8 and lactate dehydrogenase assays, and protein expression levels and OS indicatars were also measured.</p><p><strong>Results: </strong>In animal experiments, HYP intervention improved motor abilities, increased TH, Nrf2, HO-1, and Bcl-2 expressions, and reduced Bax expression compared to the MPTP group (P<0.05 or P<0.01). It also elevated GSH, GSH-Px, SOD, and CAT levels, decreased MDA, and reduced neuronal apoptosis (P<0.05 or P<0.01). Molecular docking and dynamics showed HYP binds effectively to Nrf2. Multivariate analysis revealed a strong correlation between HYP's therapeutic effect on PD and OS via the Nrf2/HO-1 pathway. In cell experiments, ML385 inhibited Nrf2/HO-1 activation by HYP (P<0.05 or P<0.01), diminishing its effect on OS and apoptosis.</p><p><strong>Conclusion: </strong>HYP can reduce OS and apoptosis by activating the Nrf2/HO-1 pathway, thereby exerting a therapeutic effect in PD.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gancao Ganjiang Decoction Inhibits Renal Cell Carcinoma Progression via PI3K-AKT and JAK-STAT Signaling Pathways.","authors":"Yi-Xue Zhang, Ji Huang, Hui-Ya Chen, Tian Tian, Zhen-Xiao Sun","doi":"10.1007/s11655-026-4155-3","DOIUrl":"https://doi.org/10.1007/s11655-026-4155-3","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the therapeutic potential of Chinese medicine prescription Gancao Ganjiang Decoction (Licorice and Dried Ginger Decoction, LDGD) against renal cell carcinoma (RCC) and to elucidate its underlying mechanisms.</p><p><strong>Methods: </strong>A mouse RCC model was established in BALB/c mice by subcutaneous injection of Renca cells. The effects of LDGD (5, 10, and 15 g/kg), cisplatin (3 mg/kg), and their combination (10 g/kg LDGD + 3 mg/kg cisplatin) on tumor growth were assessed. Ki-67 expression in tumor tissue was detected by immunohistochemistry. The anti-proliferative effects of LDGD and its 7 blood-absorbed constituents were evaluated on 769-P and 786-O human RCC cell lines using MTT and colony formation assays. Network pharmacology was conducted to predict core targets and signaling pathways. Molecular docking was performed to forecast interactions between active components of LDGD and key proteins in related signaling pathways. Western blot was used to validate phosphorylation levels of the key proteins.</p><p><strong>Results: </strong>LDGD and cisplatin inhibited mouse RCC growth in vivo. The combination of LDGD with cisplatin enhanced the tumor inhibition rate as compared with cisplatin alone. Ki-67 expression was reduced following treatments. LDGD and its blood-absorbed constituents inhibited RCC cell viability and proliferation in a time- and dose-dependent manner in vitro. Network pharmacology showed that PI3K-AKT and JAK-STAT pathways implicated in the anti-RCC effect of LDGD and its blood-absorbed constituents, and AKT1 and STAT3 were potential targets. Molecular docking suggested that isoliquiritigenin and 6-shogaol had strong binding affinity for AKT1 and STAT3. Western blot showed that LDGD suppressed phosphorylation of AKT and STAT3 in 769-P cells, while inhibited phosphorylation of STAT3 protein in 786-O cells. Isoliquiritigenin inhibited phosphorylation of AKT and STAT3 proteins in both 769-P and 786-O cells, and 6-shogaol inhibited phosphorylation of STAT3 protein in 786-O cells.</p><p><strong>Conclusion: </strong>LDGD exerts significant anti-tumor effects against RCC, possibly via suppression of AKT and STAT3 phosphorylation.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aconitine from Aconiti Lateralis Radix Praeparata (Fuzi) Suppresses Intrahepatic Cholangiocarcinoma via TOP2A: A Study Combining Machine Learning with Functional Validation.","authors":"Shuang-Nan Zhou, Jing-Jing Zhang, Da-Li Zhang, Si-Miao Yu, Yi-Jiang Liu, Ning Zhang","doi":"10.1007/s11655-026-4161-5","DOIUrl":"https://doi.org/10.1007/s11655-026-4161-5","url":null,"abstract":"<p><strong>Objective: </strong>To elucidate the therapeutic potential and mechanisms of Fuzi (Aconiti Lateralis Radix Praeparata) against intrahepatic cholangiocarcinoma (ICC).</p><p><strong>Methods: </strong>Fuzi-related targets were obtained from TCMSP, HERB, and ETCM databases, and ICC-related differentially expressed genes were retrieved from Gene Expression Omnibus. Common hub targets were identified using network pharmacology and machine learning, followed by functional enrichment and immune infiltration analyses. Effects of aconitine, a major alkaloid of Fuzi, were validated in RBE cells using qPCR, Western blot, Transwell assays, and flow cytometry.</p><p><strong>Results: </strong>Thirty-six common genes were identified, mainly enriched in metabolic and cancer-related pathways. Topoisomerase II alpha (TOP2A) and alpha1A-adrenergic receptor (ADRA1A) were identified as hub genes with high diagnostic value (area under curve>0.98). High TOP2A expression was linked to poor disease-free survival. Several immune cells, including regulatory T cells, showed altered infiltration in ICC and correlated with hub gene expression. Aconitine inhibited the proliferation, migration, and invasion of RBE cells in a dose- and time-dependent manner (P<0.05 or P<0.01). It also induced G₁ phase arrest and apoptosis, accompanied by modulation of Bcl-2 and Bax expression, and downregulation of TOP2A. TOP2A knockdown similarly reduced migration and invasion and altered Bcl-2/Bax expression, but had limited effects on apoptosis rate or cell cycle distribution.</p><p><strong>Conclusion: </strong>TOP2A was identified as Fuzi's potential therapeutic target in ICC, where its compound aconitine exerts antitumor effects by downregulating TOP2A, providing novel mechanistic insights and targeted therapy potential.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Acupuncture Combined with Estazolam for Insomnia in Hemodialysis Patients: A Single-Center, Randomized Controlled Trial.","authors":"Pei Wang, Zheng Wang, Zhong-Xin Li, Si-Hui Ma, Yan Li, Man Yu, Jiao Wang, Huan Li, Chao Yang, Xiang-Tong Liu, Min Li","doi":"10.1007/s11655-026-4164-2","DOIUrl":"https://doi.org/10.1007/s11655-026-4164-2","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of acupuncture combined with estazolam for hemodialysis patients with insomnia.</p><p><strong>Methods: </strong>This prospective, randomized controlled trial was conducted from August 15, 2022 to February 22, 2024. By the random number table method, 110 end-stage renal-disease undergoing hemodialysis patients with insomnia were randomly divided into 2 groups to receive 1 mg/d of estazolam (control group, 55 cases) or acupuncture combined with 1 mg/d of estazolam (intervention group, 55 cases) for 4 weeks, and followed up for another 4 weeks. All patients received their standard treatments and common medications. The Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety Scale (HAMA), and Chinese Medicine Syndrome Score of Insomnia (CMSSI) were the primary outcomes measured at baseline and at 2, 4, and 8 weeks, as well as clinical effectiveness before and after treatment; the second outcomes were the sleep stucture parameters assessed before and after treatment. Adverse effects were also assessed.</p><p><strong>Results: </strong>At 2, 4, and 8 weeks post-treatment, the scores of PSQI, HAMA, and CMSSI in the intervention group were lower than those in the control group (all P<0.01). At 4 weeks, the intervention group also had a significantly higher clinical effective rate than that in the control group (81.82% vs. 41.82%, P<0.01). Meanwhile, at 4 weeks post-treatment, the intervention group showed shorter sleep latency and wake time after sleep onset, higher sleep efficiency, total time in bed, sleep scores, deep sleep duration, deep sleep proportion, rapid eye movement (REM) duration and proportion, and lower light sleep proportion compared with control group (P<0.05 or P<0.01). After 4 weeks of follow-up, the intervention group still maintained higher sleep scores, deep sleep duration, deep sleep proportion, REM duration and proportion, as well as a lower light sleep proportion (P<0.05 or P<0.01). No major unfavorable adverse events were reported in both groups.</p><p><strong>Conclusion: </strong>Acupuncture combined with estazolam was superior to estazolam alone in improving clinical efficacy and sleep quality in hemodialysis patients with insomnia, with good safety and long-term efficacy. (Registration No. ChiCTR2200061967).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting SLC7A11 with Chinese Medicine for Tumor Ferroptosis Induction: From Molecular Mechanisms to Novel Precision Therapeutic Strategies.","authors":"Min Zhao, Wei Fang, Man Chen, Meng-Qi Wang, Wei Lin","doi":"10.1007/s11655-026-4153-5","DOIUrl":"https://doi.org/10.1007/s11655-026-4153-5","url":null,"abstract":"","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese Herbal Medicine Improves Pregnancy Outcome and Decreases Recurrence Rate after Surgery for Endometriosis-Associated Infertility: A Retrospective Study.","authors":"Xin-Chun Yang, Qian Han, Ran Xu, Yu Zhang, Guang Shi, Yong Liu, Wei-Wei Sun, Ying Wu, Rui-Hua Zhao","doi":"10.1007/s11655-026-4240-7","DOIUrl":"https://doi.org/10.1007/s11655-026-4240-7","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the long-term efficacy of Chinese herbal medicine (CHM) in enhancing reproductive outcomes and reducing recurrence rates among endometriosis-associated infertility women infertile women.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study is a retrospective analysis of a randomized, double-blind, placebo-controlled clinical trial implemented from May 2014 to April 2018. The study included patients with endometriosis-associated infertility who had undergone standardized laparoscopic surgery. After surgery, the participants were randomly assigned to 2 groups: the intervention group received a CHM treatment regimen, while the control group was given placebo therapy. Both groups were subjected to the same blinding procedures and received treatment for a period of 6 months. Five years after surgery, the researchers conducted follow-up with the participants and analysed the data on pregnancy outcomes and recurrence of endometriosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In this trial, a total of 202 patients with endometriosis-associated infertility (101 per group) were followed up at 5 years post-surgery for clinical pregnancy, live birth, and recurrence outcomes (101 patients per group). According to our data, pregnancies occurred in 83 (82.18%) participants in the CHM group, with a pregnancy rate of 69.02 person-years, and 70 (69.31%) participants in the placebo group, with a pregnancy rate of 42.86 person-years during pregnancy-related median follow-up of 0.75 years [interquartile range (IQR) 0.25-1.71, hazard ratio (HR) 1.451, 95% confidence interval (CI) 1.055-1.997; P=0.017]. Clinical pregnancies occurred in 80 (79.21%) participants in the CHM group, with a clinical pregnancy rate of 64.91 person-years, and in 67 (66.34%) participants in the placebo group, with a clinical pregnancy rate of 39.14 person-years over the course of a median clinical pregnancy-related follow-up of 0.83 years (IQR 0.33-1.83, HR 1.495, 95% CI 1.079-2.072; P=0.012). Live births occurred in 78 (77.23%) participants in the CHM group at a rate of 36.72 person-years and in 60 (59.41%) participants in the placebo group at a rate of 23.94 person-years during the live birth-related median follow-up of 1.79 years (IQR 1.06-3, HR 1.542, 95% CI 1.097-2.165; P=0.010). Recurrence occurred in 12 (11.88%) participants in the CHM group, with a recurrence rate of 2.95 person-years, and in 24 (23.76%) participants in the placebo group, with a recurrence rate of 7.09 person-years (HR 0.458, 95% CI 0.229-0.916; P=0.022) during the recurrence-related median follow-up of 5 years (IQR 1.0-5.0). When assessed within subgroups, the HRs of the intervention on pregnancy and recurrence were similar in participants in different layers (P interaction&gt;0.05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;CHM can improve postoperative pregnancy outcomes, shorten the time to conception, and reduce the risk of long-term recurrence in infertile patients with endometriosis after laparoscop","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Shenfu Injection in Patients with Septic Shock: A Randomized Controlled Open-Label Trial with Network Pharmacology-Based Mechanistic Insights.","authors":"Po Huang, Sha-Sha He, Shuo Feng, Wen-Jie Deng, Qing-Quan Liu, Bo Li","doi":"10.1007/s11655-026-4158-0","DOIUrl":"10.1007/s11655-026-4158-0","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the clinical efficacy of Shenfu Injection (SFI) in treating patients with septic shock through a randomized controlled trial, and explore the underling mechanisms by network pharmacology.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A prospective, single-center, randomized, open-label, parallel-controlled clinical trial was conducted between November 3, 2022 and May 4, 2025 to assess the effectiveness safety of SFI in 122 patients with septic shock (arterial blood lactate 4.5-7.0 mmol/L). Participants were randomly assigned (1:1) to the experimental or control group using stratified block randomization. In addition to the standard care recommended by guidelines, the treatment group received SFI (100 mL) combined with 0.9% saline (100 mL), while the control group received 0.9% saline (200 mL), both via intravenous infusion over 60 min once daily for 7 consecutive days and followed by a 28-d follow-up period. Primary outcomes included 28-d all-cause mortality. Secondary outcomes comprised duration of hospital and intensive care unit (ICU) stays, duration of mechanical ventilation, arterial blood lactate levels, norepinephrine dose, mean arterial pressure (MAP), lactate clearance, left ventricular ejection fraction (LVEF), creatine kinase-MB (CK-MB), and troponin I (TnI) levels on day 7. Aderverse events were recorded and compared between groups. Furthermore, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed to elucidate the underlying mechanisms.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The 28-d all-cause mortality was 41.0% (25/61) in the SFI group compared with 50.8% (31/61) in the control group (P=0.271). The 7-d all-cause mortality was significantly lower in the SFI group (4.9%, 3/61) compared with the control group (16.4%, 10/61; P=0.046). On day 7 post-enrollment, the norepinephrine dose in the SFI group was significantly lower than that in the control group [1.48 (1.12, 1.82) vs. 2.37 (1.68, 2.80) µ,g·kg&lt;sup&gt;-1&lt;/sup&gt;·min&lt;sup&gt;-1&lt;/sup&gt;, P&lt;0.01]. Similarly, lactate levels in the SFI group were significantly lower than those in the control group [3.02 (2.50, 3.33) vs. 4.37 (3.78, 4.90) mmol/L] on day 7 (P&lt;0.01). In addition, the SFI group demonstrated significantly higher lactate clearance, MAP, and LVEF, alongside significantly lower CK-MB and TnI levels compared with the control group on day 7 (all P&lt;0.01). No significant differences in adverse events were observed between two groups (5/59 vs. 3/61, P&gt;0.05). Network pharmacology analysis identified 102 intersection target genes between SFI- and septic shock-related targets, which were significantly enriched in several sepsis-related pathways, such as the IL-17, TNF, and PI3K-Akt signaling pathways.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In patients with septic shock and lactate levels of 4.5-7.0 mmol/L, adjunctive SFI did not significantly reduce 28-d all-cause mortality. However, it was associated with a significant reduction","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"579-587"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shenling Baizhu Powder Alleviated Lung Damage and Enhanced Immunoregulatory Activity in Mice with Non-Tuberculosis Mycobacterial Lung Disease.","authors":"Li-Bo Zhen, Hui-Jie Wang, Ting Mo, Xiao-Qing Ma, Yang-Min Jia, Ju-Wei Gao","doi":"10.1007/s11655-026-3957-7","DOIUrl":"10.1007/s11655-026-3957-7","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of Shenling Baizhu Powder (SLBZP) on non-tuberculous mycobacteria (NTM)-induced lung disease in mice.</p><p><strong>Methods: </strong>An NTM lung disease mouse model was established by Mycobacterium kansasii infection. C57BL/6J female mice were randomly divided into 5 groups by a random number table (n=6): negative control, NTM, SLBZP-L (2.34 g/kg), SLBZP-H (4.68 g/kg), and rifampicin (20 mg/kg). M. kansasii load in the lungs, liver, and spleen was quantified. Lung histology was performed using hematoxylin and eosin staining. Gene and cytokine expressions related to CD4⁺ T and natural killer (NK) cells were detected by enzyme linked immunosorbent assay, flow cytometry, real-time quantitative reverse transcription PCR, and Western blot, respectively.</p><p><strong>Results: </strong>SLBZP-L and SLBZP-H treatments inhibited M. kansasii growth and reduced the histological damage and granuloma lesion areas in lungs of mice (P<0.01). SLBZP-H increased interleukin (IL)-17A and interferon-gamma (IFN-γ) levels, along with the proportion of CD4⁺ T cells, NK cells, and IFN-γ⁺ NK cells, while decreased IL-10 (P<0.01). Furthermore, SLBZP-H inhibited mRNA levels of tumor necrosis factor, IL-6, IL-1β, C-C motif chemokine ligand 2, C-X-C motif chemokine ligand (CXCL) 2, GATA binding protein 3 and T-bet, and increased mRNA level of retinoic acid receptor-related orphan receptor γ (P<0.05 or P<0.01). SLBZP-L and SLBZP-H also reduced the protein expressions of CXCL13 and C-X-C chemokine receptor type 5 (P<0.05 or P<0.01).</p><p><strong>Conclusion: </strong>SLBZP alleviated NTM-induced lung damage and enhanced NK cell immune response, which might be linked to CD4⁺ T cell immunity.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"623-630"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Mechanism of Anti-tumor Effect of Trametes robiniophila Murr. (Huaier).","authors":"Ang Li, Lu-Yao Qiu, Tan-Zi Li, Li-Tao Bai, Xiao-Dong Zhao","doi":"10.1007/s11655-025-4147-8","DOIUrl":"10.1007/s11655-025-4147-8","url":null,"abstract":"","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"650-659"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Euscaphic Acid from Rosa roxburghii Tratt Exerts Anti-colorectal Cancer Activity by Inducing Mitochondrial Apoptosis through ROS/MAPK Pathway.","authors":"Mao-Yu Zhang, Bo-Wen Zhai, Han Huang, Heng Zhao, Yu-Jie Fu","doi":"10.1007/s11655-025-3837-6","DOIUrl":"10.1007/s11655-025-3837-6","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the anti-colorectal cancer (CRC) activity and its potential molecular mechanism of euscaphic acid (EA), a triterpene component from Rosa roxburghii Tratt (RRT), in vitro and in vivo.</p><p><strong>Methods: </strong>EA in RRT was isolated and analyzed for pharmacophore-based virtual screening, and enrichment analysis was performed. HCT116 and CT26 cells were used for in vitro experiments. Meanwhile, we constructed a CT26 syngeneic tumor BALB/c mice model and performed in vivo experiments. Finally, the mitochondrial apoptosis and reactive oxygen species (ROS)/mitogen-activated protein kinase (MAPK) signaling pathway-related proteins were detected by Western blot.</p><p><strong>Results: </strong>EA could inhibit the viability of HCT116 and CT26 cell lines, suppress the biological behaviors including proliferation, migration, and invasion, and induce apoptosis in vitro (P<0.05 or P<0.01). Meanwhile, in vivo experiments showed that EA significantly inhibited the growth of CRC graft tumors (P<0.05 or P<0.01). EA could decrease mitochondrial membrane potential and increase caspase-3/9 activities (P<0.05 or P<0.01). Furthermore, EA promoted the cellular ROS accumulation accompanied by activation of the MAPK signaling pathway, and interestingly, the phosphorylation level of extracellular regulated protein kinases (ERK) was higher (P<0.05 or P<0.01). In addition, the above process could be reversed by the free radical scavenger N-acetylcysteine (P<0.05 or P<0.01).</p><p><strong>Conclusions: </strong>EA could inhibit the growth of CRC cell lines both in vitro and in vivo, and activate the mitochondrial pathway through the ROS/MAPK signaling pathway to induce apoptosis in CRC cell lines. This supports the antitumor potential of triterpene acids from RRT.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"613-622"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}